NasdaqGM:XNCRBiotechs
Xencor (XNCR) Stock Drifts As Revenue Lands But Profit Path Stays Murky
Xencor stock barely flinched after earnings, ticking up less than 1% even as the quarter rewired the story around its income statement. The headline for Q2 is simple: revenue landed at US$51.2m while the company still reported a sizeable net loss of US$21.7m. For a clinical stage biotech, that mix of meaningful revenue and ongoing losses forces investors to decide whether today’s muted move reflects calm judgment or a market that is reluctant to reprice the stock until the profitability path...